Clinical Trial

Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)

Completed
View on ClinicalTrials.gov →
Summary
This is a retrospective, single-center study evaluating the effectiveness and safety of consolidative durvalumab after cCRT in LS-SCLC in real-world setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-24.
Status change: Not Yet Recruiting → Completed 2026-02-09
Trial Details
NCT Number NCT07050472
Lead Sponsor Anhui Shi, MD
Conditions Small-cell Lung Cancer
Enrollment 45 participants
Start Date 2025-08-11
Primary Completion 2025-08-12 (estimated)
Study Completion 2025-08-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-12